Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Nanocages engineered from Bacillus Calmette-Guerin facilitate protective Vγ2Vδ2 T cell immunity against Mycobacterium tuberculosis infection

Fig. 3

Effect BCG-Nanocage on ex vivo activation and expansion of Vγ2+ T cells in PBMC from non-human primates. A Typical flow cytometry panel for Vγ2+ cells gated in T cells from PBMC with or without (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 for 6 days. B Effects of (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 on Vγ2+ T cells after 6 day treatment, n = 3, *p < 0.05. C Typical flow cytometry panel for Granzyme B+ Perforin+ cells gated in Vγ2+ T cells in total T cells from PBMC with or without (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 for 6 days. D Effects of (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 on Vγ2+ Granzyme B+ Perforin+ cells in T cells after 6 day treatment, n = 3, *p < 0.05. E Typical flow cytometry panel for Granulysin + IFN-γ + cells gated in Vγ2+ T cells from PBMC with or without (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 for 6 days. F Effects of (co-)stimulation using BCG/IL2, BCG-Nanocage/IL2 or IL2 on Vγ2+ Granulysin + IFN-γ+ cells in T cells after 6 day treatment, n = 3, *p < 0.05

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us